Celiac DiseaseNCT07832994
Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in Adolescents
A study testing walking exercise in people with Celiac Disease and Metabolic Syndrome, run by Cairo University at 1 site in Egypt.
Trial summary
metabolic syndrome and fatty liver is common in adolescents with celiac diseases. exercise may control these cardiovascular risk factors Read more about this study
- Who is it for?
- Ages 13 to 17 years, women only
- Conditions the study is for
- Celiac Disease, Metabolic Syndrome, Non Alcoholic Fatty Liver
- What is being tested?
- walking exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Aug 2026to 15 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 17 years
- Women only
- No healthy volunteers
- Child
Who may be able to join
- celiac disease
- metabolic syndrome
- nonalcholic fatty liver
Who cannot join
- cardiac disease
- renal failure
- respiratory disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Giza, Dokki
ali ismail, lecturer, 02 01005154209, ali.mohamed@pt.cu.edu.eg
About this study
metabolic syndrome and fatty liver is common in adolescents with celiac diseases. exercise may control these cardiovascular risk factors
Read the detailed description
forty metabolic syndrome and fatty liver female adolescents with celiac diseases will assigned to exercise group or control group. the group will contain twenty patients. control group will be wait list. exercise group will perform 40 minutes of walking on a treadmill three times weekly for three months.
- Being tested
- walking exercise
- Medical subject headings
- Celiac Disease, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
walking exerciseBehavioural
twenty metabolic syndrome and fatty liver female adolescents with celiac diseases will will perform 40 minutes of walking on a treadmill three times weekly for three months.
| Study group | Role | What they receive |
|---|---|---|
| group I | Experimental | twenty metabolic syndrome and fatty liver female adolescents with celiac diseases will will perform 40 minutes of walking on a treadmill three times weekly for three months. Receives: Behavioral: walking exercise |
| group II | No intervention | twenty metabolic syndrome and fatty liver female adolescents with celiac diseases will be wait list for three months. |
What is being measured
The primary outcome is the main question the study is designed to answer.
alanine transamianse
It will be asssessed in plasma
Measured: It will be measured after 12 weeks
Secondary outcomes (10)
Asparate tranamianse
it will be assessed in plasma
Measured: It will be measured after 12 weeks
gamma glutamyl transferase
it will be assessed in plasma
Measured: it will be measured after 12 weeks
alkaline phosphatase
it will be assessed in plasma
Measured: it will be measured after 12 weeks
Body mass index
it wil be measured with empty stomach and bladder
Measured: it will be assessed after 12 weeks
wasit circumference
it will be assessed at the level of umbilicus
Measured: it will be assessed after 12 weeks
systolic blood pressure
it will be assessed at level of brachial artery
Measured: it will be assessed after 12 weeks
diastolic blood pressure
it will be assessed at level of brachial artery
Measured: it will be assessed after 12 weeks
blood glucose
it will be measured in fasting status in blood
Measured: it will be assessed after 12 weeks
high density lipoproteins
it will be assessed in plasma
Measured: it will be assessed after 12 weeks
triglycerides
it will be assessed in plasma
Measured: it will be assessed after 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start15 Aug 2026
- Primary completion15 Dec 2026 (estimated)
- Study completion15 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Celiac DiseaseStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Mohamed Ali ismail, Cairo University
- Investigators
- Ali MA Ismail, PHD, Principal investigator, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07832994
- Sponsor's protocol ID
- IRB000-14233-103
- Status last verified
- Sep 2026
- First submitted
- 16 Sep 2026
- Last updated
- 22 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in Adolescents
- ClinicalTrials.gov ID
- NCT07832994
- Acronym / sponsor ID
- IRB000-14233-103
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 15 Aug 2026 (actual)
- Primary completion
- 15 Dec 2026 (estimated)
- Study completion
- 15 Dec 2026 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
metabolic syndrome and fatty liver is common in adolescents with celiac diseases. exercise may control these cardiovascular risk factors
Detailed description
forty metabolic syndrome and fatty liver female adolescents with celiac diseases will assigned to exercise group or control group. the group will contain twenty patients. control group will be wait list. exercise group will perform 40 minutes of walking on a treadmill three times weekly for three months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group I | Experimental | Behavioral: walking exercisetwenty metabolic syndrome and fatty liver female adolescents with celiac diseases will will perform 40 minutes of walking on a treadmill three times weekly for three months. |
| group II | No intervention | –twenty metabolic syndrome and fatty liver female adolescents with celiac diseases will be wait list for three months. |
Who may qualify
- Ages
- 13 to 17 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- celiac disease
- metabolic syndrome
- nonalcholic fatty liver
Key exclusion criteria (3 listed)
- cardiac disease
- renal failure
- respiratory disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| walking exercisetwenty metabolic syndrome and fatty liver female adolescents with celiac diseases will will perform 40 minutes of walking on a treadmill three times weekly for three months. | Behavioural | group I |
Primary outcome
alanine transamianse
Time frame: It will be measured after 12 weeks
It will be asssessed in plasma
10 secondary outcomes
Asparate tranamianse
Time frame: It will be measured after 12 weeks
gamma glutamyl transferase
Time frame: it will be measured after 12 weeks
alkaline phosphatase
Time frame: it will be measured after 12 weeks
Body mass index
Time frame: it will be assessed after 12 weeks
wasit circumference
Time frame: it will be assessed after 12 weeks
systolic blood pressure
Time frame: it will be assessed after 12 weeks
diastolic blood pressure
Time frame: it will be assessed after 12 weeks
blood glucose
Time frame: it will be assessed after 12 weeks
high density lipoproteins
Time frame: it will be assessed after 12 weeks
triglycerides
Time frame: it will be assessed after 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
Related trials for Celiac Disease
Active, not recruitingEarly Phase 1
VTP-1000 in Adults With Celiac Disease
Celiac Disease
RecruitingObservational study
Impact of Mediterranean Diet and Processed Food Consumption on Gastrointestinal Symptoms in Coeliac Patients on a Gluten-Free Diet
Celiac Disease, Gluten-free Diet
Recruiting
GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)
Celiac Disease in Children, Nutrition Disorder, Child
RecruitingObservational study
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
Celiac Disease
RecruitingObservational study
Pathogenic Study of Adult Immune Enteropathies
Celiac Disease, Autoimmune Enteropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ali MA Ismail, PHD principal investigator
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing walking exercise in people with Celiac Disease and Metabolic Syndrome, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ali MA Ismail, PhD (+201005154209, ali.mohamed@pt.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
alanine transamianse (time frame: It will be measured after 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.